18 December 2025
Latham Advises Norgine on Exclusive Licensing Agreement With Vir Biotechnology
Advising firms
Deal team
9 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Oliver Mobasser Lead | Latham & Watkins LLP | Counsel | Not stated | London |
| Eliot Choy | Latham & Watkins LLP | Counsel | Not stated | New York |
| Robbie McLaren | Latham & Watkins LLP | Partner | Not stated | London |
| Luke Nauth | Latham & Watkins LLP | Associate | Not stated | London |
| Simon Skinner | Latham & Watkins LLP | Partner | tax | London |
| Tom O'Malley | Latham & Watkins LLP | Associate | tax | Not stated |
| Eveline Van Keymeulen | Latham & Watkins LLP | Partner | regulatory | Paris |
| Chris Schott | Latham & Watkins LLP | Partner | regulatory | Washington, D.C. |
| Grégoire Paquet | Latham & Watkins LLP | Associate | regulatory | Paris |
Stated terms
- Stated value
- EUR 55m (€55 million)
- What the figure measures
- Total transaction value
- Client
- Norgine
- Counterparties
- Vir Biotechnology